Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases.

Polke M, Kirsten D, Teucher B, Kahn N, Geissler K, Costabel U, Herth FJF, Kreuter M.

Respiration. 2020 Jan 30;99(2):119-124. doi: 10.1159/000504677. [Epub ahead of print]

PMID:
32000164
2.

Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Kohno N, Komoto D, Awai K, Shime N, Bonella F, Guzman J, Kühl H, Costabel U, Hattori N.

J Clin Med. 2019 Nov 24;8(12). pii: E2069. doi: 10.3390/jcm8122069.

3.

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G.

Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28.

PMID:
31575509
4.

Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern.

Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntasiou M, Katsaras M, Costabel U, Wells A, Bouros D.

Eur Respir J. 2019 Nov 14;54(5). pii: 1901144. doi: 10.1183/13993003.01144-2019. Print 2019 Nov. No abstract available.

PMID:
31320457
5.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

6.

Quantitative Lipidomics in Pulmonary Alveolar Proteinosis.

Griese M, Bonella F, Costabel U, de Blic J, Tran NB, Liebisch G.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):881-887. doi: 10.1164/rccm.201901-0086OC.

PMID:
31002528
7.

[The Role of Air Pollutants for Health - A Reply to the Expert Opinion of the International Society for Environmental Epidemiology (ISEE) and the European Respiratory Society (ERS)].

Köhler D, Hetzel M, Klingner M, Koch T, Ewig S, Becher G, Lindemann H, Voshaar T, Costabel U.

Pneumologie. 2019 May;73(5):274-287. doi: 10.1055/a-0873-3574. Epub 2019 Apr 16. German.

PMID:
30991436
8.

Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective.

Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J, Costabel U, Drent M.

Lung. 2019 Apr;197(2):163. doi: 10.1007/s00408-019-00221-8.

9.

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia.

Lyu Y, Boerner E, Theegarten D, Guzman J, Kreuter M, Costabel U, Bonella F.

Respiration. 2019;98(1):29-37. doi: 10.1159/000496483. Epub 2019 Mar 29.

PMID:
30928980
10.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

11.

The Burden of Sarcoidosis Symptoms from a Patient Perspective.

Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J, Costabel U, Drent M.

Lung. 2019 Apr;197(2):155-161. doi: 10.1007/s00408-019-00206-7. Epub 2019 Feb 16. Erratum in: Lung. 2019 Apr 8;:.

12.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Kolilekas L, Costabel U, Tzouvelekis A, Tzilas V, Bouros D.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800994. doi: 10.1183/13993003.00994-2018. Print 2019 Feb. No abstract available.

PMID:
30765482
13.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

14.

Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients.

Bessa V, Bonella F, Ohshimo S, Weinreich G, Kleibrink B, Costabel U, Aigner C, Kamler M, Taube C, Sommerwerck U.

Transpl Immunol. 2019 Feb;52:40-44. doi: 10.1016/j.trim.2018.10.006. Epub 2018 Nov 1.

PMID:
30391371
15.

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.

Wang Z, Bonella F, Li W, Boerner EB, Guo Q, Kong X, Zhang X, Costabel U, Kreuter M.

Respiration. 2018;96(6):571-587. doi: 10.1159/000492336. Epub 2018 Oct 11. Review.

PMID:
30308515
16.

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.

PMID:
30224318
17.

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.

Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G.

Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.

18.

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, Maurer O, Heinemann S, Costabel U, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells A, Vasakova M, Pesci A, Sofia M, Klepetko W, Seeger W, Drakopanagiotakis F, Crestani B.

Respir Res. 2018 Jul 28;19(1):141. doi: 10.1186/s12931-018-0845-5.

19.

An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Ohshimo S, Costabel U, Shime N.

Respir Investig. 2018 Mar;56(2):97-99. doi: 10.1016/j.resinv.2017.12.003. Epub 2017 Dec 27. No abstract available.

PMID:
29548662
20.

[DGP Interstitial Lung Disease Patient Questionnaire].

Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Wälscher J, Wirtz H, Kirsten D.

Pneumologie. 2018 Jun;72(6):446-457. doi: 10.1055/s-0044-100207. Epub 2018 Feb 21. German.

PMID:
29466814
21.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

22.

Phenotypes of organ involvement in sarcoidosis.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O'Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.

23.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

24.

Serum YKL-40 in workers at an indium-tin oxide production facility - Reply.

Bonella F, Costabel U; all co-authors.

Respirology. 2018 Mar;23(3):342. doi: 10.1111/resp.13237. Epub 2017 Dec 15. No abstract available.

PMID:
29243860
25.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

26.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

27.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

28.

Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Ohshimo S, Guzman J, Costabel U, Bonella F.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170012. doi: 10.1183/16000617.0012-2017. Print 2017 Sep 30. Review.

29.

Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity.

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Bonella F.

Rev Port Pneumol (2006). 2017 Nov - Dec;23(6):352-355. doi: 10.1016/j.rppnen.2017.06.006. Epub 2017 Aug 3.

30.

[Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].

Behr J, Günther A, Kreuter M, Koschel D, Prasse A, Pfeifer M, Costabel U.

Pneumologie. 2017 Sep;71(9):567-579. doi: 10.1055/s-0043-109856. Epub 2017 Aug 3. Review. German.

PMID:
28772332
31.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):474. doi: 10.1055/s-0043-115504. Epub 2017 Jul 5. German. No abstract available.

PMID:
28679139
32.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U.

Respirology. 2017 Oct;22(7):1371-1378. doi: 10.1111/resp.13082. Epub 2017 May 31.

33.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):460-474. doi: 10.1055/s-0043-106160. Epub 2017 May 30. German. Erratum in: Pneumologie. 2017 Jul;71(7):474.

PMID:
28558396
34.

Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Costabel U, Stansen W, Stowasser S.

Am J Respir Crit Care Med. 2017 May 1;195(9):1275. doi: 10.1164/rccm.201610-2155LE. No abstract available.

PMID:
28459331
35.

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.

Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.

36.

Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications.

Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V.

Respiration. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

37.

FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N.

Respir Med. 2017 Feb;123:105-109. doi: 10.1016/j.rmed.2016.12.007. Epub 2016 Dec 22.

38.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
39.

Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.

Long X, He X, Ohshimo S, Griese M, Sarria R, Guzman J, Costabel U, Bonella F.

Eur Respir J. 2017 Feb 23;49(2). pii: 1501924. doi: 10.1183/13993003.01924-2015. Print 2017 Feb.

40.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Nov;48(5):1524-1526. doi: 10.1183/13993003.01482-2016. No abstract available.

41.

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.

Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M.

Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5.

42.

[German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"].

Kreuter M, Birring SS, Wijsenbeek M, Wapenaar M, Oltmanns U, Costabel U, Bonella F.

Pneumologie. 2016 Nov;70(11):742-746. Epub 2016 Sep 21. German.

43.

Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply.

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJF, Costabel U.

Lancet Respir Med. 2016 Sep;4(9):e48. doi: 10.1016/S2213-2600(16)30235-1. No abstract available.

PMID:
27599251
44.

Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Orphanet J Rare Dis. 2016 Aug 31;11(1):115. doi: 10.1186/s13023-016-0497-9.

45.

Sarcoidosis in America. Analysis Based on Health Care Use.

Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, Judson MA, Wolff G.

Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. doi: 10.1513/AnnalsATS.201511-760OC.

PMID:
27509154
46.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

47.

[Epidemiology and Clinical Presentation of Sarcoidosis].

Costabel U, Wessendorf TE, Bonella F.

Klin Monbl Augenheilkd. 2017 Jun;234(6):790-795. doi: 10.1055/s-0042-105569. Epub 2016 Jul 25. Review. German.

PMID:
27454307
48.

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Chest. 2016 Jul;150(1):251-3. doi: 10.1016/j.chest.2016.04.030. No abstract available.

49.

Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition.

Strek ME, Costabel U.

Curr Opin Pulm Med. 2016 Sep;22(5):442-9. doi: 10.1097/MCP.0000000000000298. Review.

PMID:
27379968
50.

MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.

Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U.

Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2.

Supplemental Content

Loading ...
Support Center